Expression of matrix metalloproteinases in gastric carcinoma and possibility of clinical application of matrix metalloproteinase inhibitor in vivo.
Otani
Y
Y
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan. otaniy@med.keio.ac.jp
Kubota
T
T
Sakurai
Y
Y
Igarashi
N
N
Yokoyama
T
T
Kimata
M
M
Wada
N
N
Kameyama
K
K
Kumai
K
K
Okada
Y
Y
Kitajima
M
M
D000081:Acetamides / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017364:Collagenases / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D020781:Matrix Metalloproteinase 1; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000235:genetics*; D051379:Mice; D008819:Mice, Nude; D012333:RNA, Messenger / Q000235:genetics; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D014158:Transcription, Genetic; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D000081:Acetamides; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; C117981:R 94138; D012333:RNA, Messenger; D017364:Collagenases; D008666:Metalloendopeptidases; D020781:Matrix Metalloproteinase 1